Skip to main content

Table 2 Influence of demographic and clinical data on MTX intolerance

From: Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis

 

MTX tolerant

MTX intolerant

p

Female Gender

74/106

67/90

0. 525

Age

9,67 ± 4,42

10,83 ± 3,89

0. 055

Age at diagnosis

5,53 ± 4,09

5,13 ± 4,04

0. 495

Disease duration

4,14 ± 3,54

5,70 ± 3,78

0. 003*

Duration of MTX treatment

1,83 ± 2,33

2,45 ± 2,32

0. 064

MTX dose/m2 BSA

12,29 ± 2,08

11,63 ± 2,00

0. 026

s.c. dosing

47/106

40/90

1. 000

Folic acid supplementation

103/106

81/90

0. 069

Elevated LFT

18/106

22/90

0. 217

Treatment with TNFA

47/106

33/90

0. 309

Treatment with NSAID

37/106

31/90

1. 000

  1. BSA body surface area, LFT liver function tests, TNFA TNFα antagonist, NSAID non-steroidal anti-inflammatory drug
  2. * significant after Bonferroni correction